Helicobacter pylori proteins and structures (H. pylori)

Helicobacter pylori (H. pylori) is a Gram-negative, spiral-shaped bacterium that colonizes the human gastric mucosa, affecting approximately half of the global population [1][2]. The "Multiple H. pylori proteins and structures" refers to the collective set of molecular targets within the bacterium that are essential for its survival, colonization, and virulence. Key components include the enzyme urease, which allows the bacterium to survive in the acidic stomach environment by producing ammonia, and virulence factors such as Vacuolating cytotoxin A (VacA) and Cytotoxin-associated gene A (CagA), which disrupt host cell signaling and promote inflammation [3][4]. These structures are the primary targets for pharmacological intervention; for instance, penicillin-binding proteins (PBPs) are targeted by beta-lactam antibiotics, while the bacterial ribosome is targeted by macrolides and tetracyclines [5][6]. Chronic infection by H. pylori is a major risk factor for the development of peptic ulcers, gastric adenocarcinoma, and MALT lymphoma [1][2]. Effective treatment typically requires a combination of antibiotics and acid-suppressing agents to eradicate the bacteria and prevent disease progression [5].

Other names

H. pylori proteomeHelicobacter pylori virulence factorsH. pylori essential proteinsGastric helicobacter components

Drugs targeting H. pylori components operate through several distinct mechanisms: amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs); clarithromycin and tetracycline inhibit protein synthesis by binding to the 50S and 30S ribosomal subunits, respectively; metronidazole causes DNA strand breakage through the formation of reactive intermediates; and levofloxacin inhibits DNA replication by targeting DNA gyrase [5][6][9].